Clinical Trial Detail

NCT ID NCT02419560
Title Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL
Recruitment Unknown status
Gender both
Phase Phase I
Variant Requirements No
Sponsors Craig Portell, MD
Indications

mantle cell lymphoma

Therapies

Ibrutinib + Venetoclax

Age Groups: adult

No variant requirements are available.